LIXTE Biotechnology Holdings (NASDAQ: LIXT) has filed its first-quarter 2026 Form 10-Q, detailing continued advancement of its lead oncology candidate, LB-100. The company reported expansion of its ovarian cancer trial following favorable safety findings when combining LB-100 with immunotherapy. LIXTE also highlighted continued growth at its recently acquired Liora Technologies Europe subsidiary, as part of a broader strategic expansion to strengthen its oncology pipeline and treatment development capabilities.
LB-100 is a first-in-class clinical PP2A inhibitor that has demonstrated tolerability in cancer patients at doses associated with anti-cancer activity. Based on published preclinical data, LB-100 has the potential to significantly enhance chemotherapies and immunotherapies and improve outcomes for patients with cancer. The compound is part of a pioneering effort in an entirely new field of cancer biology – activation lethality – that is advancing a new treatment paradigm. LIXTE’s novel approach is covered by a comprehensive patent portfolio, with proof-of-concept clinical trials currently in progress for Ovarian Clear Cell Carcinoma, Metastatic Colon Cancer and Advanced Soft Tissue Sarcoma.
Through its wholly owned subsidiary, Liora Technologies Europe Ltd., LIXTE is also pioneering the development of electronically controlled proton therapy systems for treating tumors. Liora’s proprietary flagship technology, the LiGHT System, is believed to provide significant advantages over currently available technologies for treating tumors with proton therapy. Additional information about Liora Technologies can be found at www.lioratechnologies.com.
The announcement follows LIXTE's recent acquisition of Liora Technologies, marking a strategic expansion beyond small molecule oncology into advanced radiation therapy. This diversification aims to create a more robust pipeline and potentially synergistic treatment approaches. The company's dual focus on targeted therapies and next-generation proton therapy positions it to address multiple facets of cancer treatment.
LIXTE's progress comes amid a competitive landscape for oncology drug development. The expansion of the ovarian cancer trial is particularly noteworthy given the high unmet need in ovarian clear cell carcinoma, a rare and aggressive form of the disease. If successful, LB-100 could offer a new treatment option for patients who have limited alternatives.
Investors can find the latest news and updates relating to LIXT in the company’s newsroom at https://ibn.fm/LIXT. The full press release is available at https://ibn.fm/oHzhK.
